Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

Living medicines

Home » Health and medicine » Living medicines » Page 2

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Azitra Receives Ongoing Support for Its Netherton Development Program from the National Science Foundation (NSF)

Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions

Pieter Rottiers

ActoBio Therapeutics™ CEO Pieter Rottiers on the potential to cure disease with living medicines

Jim Collins

Why now is the time for programmable living medicines: insights from Jim Collins, Aoife Brennan, and Jason Kelly

Wendell Lim

Synthetic biologist Wendell Lim talks about using living cells to raise the bar on cancer therapy

Tim Lu

Senti Biosciences’ CEO Tim Lu talks about the challenges facing cell therapies — and how we can overcome them

Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease